AMRN

Validea's Upgrade for AMRN: Validea's Price/Sales Investor model, based on Kenneth Fisher's strategy, upgraded Amarin Corporation PLC (AMRN) from 28% to 60% due to improved fundamentals and valuation, indicating growing interest in the stock.

Company Overview: Amarin Corporation is a pharmaceutical company focused on developing therapeutics for cardiovascular health, primarily through its lead product, Vascepa, which is used to reduce triglyceride levels in patients with severe hypertriglyceridemia.

Kenneth Fisher's Background: Kenneth Fisher, a prominent money manager and author, is known for popularizing the price/sales ratio as a stock evaluation tool and is the founder of Fisher Investments, located in a forest preserve to encourage independent thinking away from Wall Street.

Validea's Investment Research: Validea provides investment research based on the strategies of successful investors like Warren Buffett and Benjamin Graham, offering stock analysis and model portfolios aimed at long-term market outperformance.

New Analysis on Icosapent Ethyl: A post hoc analysis from the REDUCE-IT study shows that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, regardless of aspirin use, reinforcing its role in comprehensive cardiovascular risk management.

FDA Update on Fibrates: The FDA has updated labeling for fibrates, indicating they do not provide cardiovascular benefits when used with statins, highlighting the need for more effective therapies to address residual cardiovascular risk.

Commitment to Cardiovascular Care: Amarin Corporation emphasizes its dedication to advancing cardiovascular care and raising awareness about the importance of FDA-approved therapies like VASCEPA (icosapent ethyl) for patients with elevated triglycerides.

Efficacy and Safety Profile: The analysis indicates that icosapent ethyl offers cardiovascular protection beyond standard therapies without additional safety concerns, addressing a critical evidence gap in cardiovascular treatment.